Business highlights in Q4 2023
- In October the company announced positive results from its Phase IIb clinical trial with pudafensine (IP2015) for the treatment of erectile dysfunction (ED). The study data analysis has demonstrated statistically significant and clinically relevant efficacy in ED-related endpoints and no observations of critical adverse events. The positive results, both regarding efficacy and safety, support further development of pudafensine aiming at registration and launch in this patient group with significant unmet medical need.
Business highlights after this reporting period
- In January the company announced that it has expanded its position to a broader Sexual Health Franchise including both male Erectile Dysfunction (ED) and Female Sexual Dysfunction (FSD) indications and intensifies its business development efforts.
- In January the company announed the issuance of new shares and directed share buyback, as well as the sale of shares in connection with the long-term incentive program for 2021.
- In February the company announced that MAC Clinical Research has converted its convertible loan into shares in Initiator Pharma.
Financial Highlights
| Fourth Quarter (2023-10-01 – 2023-12-31) |
| Net revenue were TDKK 0 (0) |
| Operating loss, EBIT was TDKK -4,279 (-6,477) |
| Earnings per share before and after dilution was DKK 0.03 (-0.06) |
| Cash: TDKK 24,336 (39,112) |
| Solidity: 37% (72%) |
| Full Year (2023-01-01 – 2023-12-31) |
| Net revenues were TDKK 0 (0) |
| Operating loss, EBIT was TDKK -27,029 (-41,740) |
| Earnings per share before and after dilution was DKK –0.44 (-0.73) |
Solidity: equity divided by assets.
The Board of Directors have decided that interim reports will be published in English only.
Link to the full report
https://www.initiatorpharma.com/en/investors/reports-and-presentations/